Abstract：OBJECTIVE: To study the roles of platelet (PLT) and its regulating factors, megakaryocyte, thrombopoietin (TPO) and transforming growth factor β1 (TGF-β1), in immune vasculitis in young rabbits. METHODS: An experimental model of Kawasaki disease (KD) of weanling rabbits was reproduced by bovine serum. PLT count, total number and differentiating count of megakaryocyte, and serum TPO and TGF-β1 levels were measured 0, 4, 8, 12, 16, 20, 24 and 28 days after KD induction. Pathological analysis of coronary artery, liver, spleen, kidney and brain was performed 17 and 28 days after KD induction. RESULTS: In the KD group, PLT count, the total number of megakaryocyte, and the middle board megakaryocyte percentage increased 12, 16, 20, 24 and 28 days; serum TPO level increased 8, 12, 16, 20, 24 and 28 days; serum TGF-β1 level increased 16, 20, 24 and 28 days after KD induction compared with those in the normal control group (P<0.05). The pathological examinations of coronary artery, liver, spleen, kidney and brain showed severe inflammatory injuries of tiny arteries and small/medium-sized arteries 17 and 28 days after KD induction, respectively in the KD group. The aortas were showed as mild inflammatory injuries. CONCLUSIONS: PLT, megakaryocyte, TPO and TGF-β1 participate in the pathogenesis of KD, and they may play an important role in the injuries of immune vasculitis. This suggests that they may serve as markers for the assessment of severity in KD.［Chin J Contemp Pediatr, 2009, 11 (10):850-853］
TIAN Xin,HE Xiang-Ling,FANG Yi-Bing et al. Roles of platelet and its regulating factors in immune vasculitis in young rabbits[J]. CJCP, 2009, 11(10): 850-853.
［1］Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association［J］. Pediatrics, 2004, 114(6):1708-1733.
［2］Hamada H, Terai M, Honda T, Kohno Y. Marked pleural and pericardial effusion with elevated vascular endothelial growth factor production:an uncommon complication of Kawasaki disease［J］. Pediatr Int, 2005, 47(1):112-114.
［5］Onouchi Z, Ikuta K, Nagamatsu K, Tamiya H, Sakakibara Y, Ando M. Coronary artery aneurysms develop in weanling rabbits with serum sickness but not in mature rabbits.An experimental model for Kawasaki disease in humans［J］. Angidogy, 1995, 46(8):679-687.
［6］胡亚美,江载芳.实用儿科学［M］.第6版.北京:人民卫生出版社,2002，655.
［7］Cummings C, McCarthy P, VanHoff J, Porter G Jr. Kawasaki disease associated with reactive hemophagocytic lymphohistiocytosis［J］. Pediatr Infect Dis J, 2008, 27(12):1116-1118.
［9］Hitchcock IS, Fox NE, Prévost N, Sear K, Shattil SJ, Kaushansky K. Roles of focal adhesion kinase (FAK) in megakaryopoiesis and platelet function:studies using a megakaryocyte lineage specific FAK knockout［J］. Blood, 2008, 111(2):596-604.
［10］Ishiguro A, Ishikita T, Shimbo T. Elevation of serum thrombopoietin precedes thrombocytosis in Kawasaki disease［J］.Thromb Haemost, 1998, 79(6):1096-1100.
［11］Miura N, Terai M, Meng YG. Serum thrombopoietin levels in Kawasaki disease［J］.Br J Haematol, 1998, 100(2):387-388.
［12］Terai M, Yasukawa K, Narumoto S, Tateno S, Oana S, Kohno Y. Vascular endothelial growth factor in acute Kawasaki disease［J］.Am J Cardiol, 1999, 83(11):1592.
［15］Akiyama T, Matsunaga T, Temi T, Miyanishi K, Tanaka I, Sato T, et al. Involvement of transforming growth factor-beta and thrombopoietin in the pathogenesis of mydlodysptastic syndrome with myelofibrosis［J］.Leukemia, 2005, 19(9):1558-1566.
［16］Suganami Y, Kawashima H, Hasegawa D, Sato S, Hoshika A. Clinical application of rapid assay of serum interleukin-6 in Kawasaki disease［J］.Pediatr Int, 2008, 50(2):264-266.
［18］Wang H, Wang H, Cheng P. Effects of serum of Kawasaki disease on PDGF expression in monocytes and on endothelial cell apoptosis［J］.J Tongji Med Univ, 1999, 19(2):105-107.
